BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28299476)

  • 21. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research.
    Espinosa Fernandez JR; Eckhardt BL; Lee J; Lim B; Pearson T; Seitz RS; Hout DR; Schweitzer BL; Nielsen TJ; Lawrence OR; Wang Y; Rao A; Ueno NT
    PLoS One; 2020; 15(4):e0231953. PubMed ID: 32353087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brain-derived neurotrophic factor (BDNF) -TrKB signaling modulates cancer-endothelial cells interaction and affects the outcomes of triple negative breast cancer.
    Tsai YF; Tseng LM; Hsu CY; Yang MH; Chiu JH; Shyr YM
    PLoS One; 2017; 12(6):e0178173. PubMed ID: 28604807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COL8A1 enhances the invasion/metastasis in MDA-MB-231 cells via the induction of IL1B and MMP1 expression.
    Sagara A; Miura S; Kobinata A; Naganawa R; Yaginuma S; Saito S; Saito R; Kominato H; Yumoto T; Sato F
    Biochem Biophys Res Commun; 2023 Jan; 642():145-153. PubMed ID: 36577251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of distinct triple-negative breast cancer subtypes on misdiagnosis and diagnostic delay.
    Elfgen C; Varga Z; Reeve K; Moskovszky L; Bjelic-Radisic V; Tausch C; Güth U
    Breast Cancer Res Treat; 2019 Aug; 177(1):67-75. PubMed ID: 31154578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.
    Masuda H; Harano K; Miura S; Wang Y; Hirota Y; Harada O; Jolly MK; Matsunaga Y; Lim B; Wood AL; Parinyanitikul N; Jin Lee H; Gong G; George JT; Levine H; Lee J; Wang X; Lucci A; Rao A; Schweitzer BL; Lawrence OR; Seitz RS; Morris SW; Hout DR; Nakamura S; Krishnamurthy S; Ueno NT
    JCO Precis Oncol; 2022 Mar; 6():e2000368. PubMed ID: 35294223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Features of Triple Negative Breast Cancer: Microarray Evidence and Further Integrated Analysis.
    He J; Yang J; Chen W; Wu H; Yuan Z; Wang K; Li G; Sun J; Yu L
    PLoS One; 2015; 10(6):e0129842. PubMed ID: 26103053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tryptophan hydroxylase 1 and 5-HT
    Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
    Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.
    Lee YM; Oh MH; Go JH; Han K; Choi SY
    Genes Genomics; 2020 Dec; 42(12):1381-1387. PubMed ID: 33145728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers.
    Limsakul P; Choochuen P; Charupanit G; Charupanit K
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
    Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
    Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bcl-3 promotes proliferation and chemosensitivity in BL1 subtype of TNBC cells.
    Huo J; Chen X; Zhang H; Hu Y; Jiang Y; Liu S; Zhang X
    Acta Biochim Biophys Sin (Shanghai); 2018 Nov; 50(11):1141-1149. PubMed ID: 30289427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocan as a prognostic biomarker of triple-negative breast cancer.
    Sagara A; Igarashi K; Otsuka M; Kodama A; Yamashita M; Sugiura R; Karasawa T; Arakawa K; Narita M; Kuzumaki N; Narita M; Kato Y
    Breast Cancer Res Treat; 2017 Jan; 161(2):269-278. PubMed ID: 27888420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
    Yi YW; You K; Bae EJ; Kwak SJ; Seong YS; Bae I
    Int J Oncol; 2015 Jul; 47(1):122-32. PubMed ID: 25955731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients.
    Ring BZ; Hout DR; Morris SW; Lawrence K; Schweitzer BL; Bailey DB; Lehmann BD; Pietenpol JA; Seitz RS
    BMC Cancer; 2016 Feb; 16():143. PubMed ID: 26908167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes
    Olsson M; Larsson P; Johansson J; Sah VR; Parris TZ
    Front Cell Dev Biol; 2023; 11():1237673. PubMed ID: 37771376
    [No Abstract]   [Full Text] [Related]  

  • 38. Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
    Suntiparpluacha M; Chanthercrob J; Sa-Nguanraksa D; Sitthikornpaiboon J; Chaiboonchoe A; Kueanjinda P; Jinawath N; Sampattavanich S
    PeerJ; 2023; 11():e15350. PubMed ID: 37334114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
    Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
    Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reverse engineering of triple-negative breast cancer cells for targeted treatment.
    Bluemel L; von Wahlde MK; Tio J; Kiesel L; Bernemann C
    Maturitas; 2018 Feb; 108():24-30. PubMed ID: 29290211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.